Real-life long-term omalizumab therapy in children with severe allergic asthma

Antoine Deschildre; Christophe Marguet; Carole Langlois; Isabelle Pin; Jean-Luc Rittié; Jocelyne Derelle; Rola Abou Taam; Michael Fayon; Jacques Brouard; Jean Christophe Dubus; Daniel Siret; Laurence Weiss; Guillaume Pouessel; Laurent Beghin; Jocelyne Just

doi:10.1183/09031936.00008115

Real-life long-term omalizumab therapy in children with severe allergic asthma

Eur Respir J. 2015 Sep;46(3):856-9. doi: 10.1183/09031936.00008115. Epub 2015 May 28.

Authors

Affiliations

¹ Unité de pneumologie et allergologie pédiatriques, pôle enfant, clinique de pédiatrie Jeanne de Flandre, CHRU de Lille, Université Nord de France, Lille, France antoine.deschildre@chru-lille.fr.
² Pediatric respiratory disease and allergy unit, University Charles Nicolle Hospital, EA3830 GHRV, Rouen University, Rouen, France.
³ Département de biostatistiques, CHRU de Lille, Université Nord de France, Lille, France.
⁴ Pédiatrie, Pôle Couple Enfants, CHU de Grenoble, INSERM U823, Institut Albert Bonniot, Université Joseph Fourier, Grenoble, France.
⁵ Allergologie - Pneumologie, Hôpital des Enfants, CHU Purpan Toulouse, Toulouse, France.
⁶ Service de pédiatrie 1, Hôpital d'enfants de Brabois, CHU Nancy, Vandoeuvre-Lés-Nancy, France.
⁷ Service de pneumologie et d'allergologie pédiatriques, hôpital Necker-Enfants-Malades, Paris, France.
⁸ CHU de Bordeaux, Département de Pédiatrie, Centre d'Investigation Clinique (CIC 0005), Bordeaux, France.
⁹ CHU de Caen, Dept of Pediatrics, Research unit EA 4655 U2RM, Caen, France.
¹⁰ Unité de pneumologie et médecine infantile, CNRS, URMITE 6236, CHU Timone-Enfants, Aix-Marseille Université, Marseille, France.
¹¹ Service de Pédiatrie, CH de Saint-Nazaire, Saint-Nazaire, France.
¹² Pôle médico-chirurgical de Pédiatrie, CHU de Hautepierre, Strasbourg, France.
¹³ Service de pediatrie, CH Roubaix, Roubaix, France.
¹⁴ CIC-9301-Inserm-CHU (Centre d'Investigation Clinique de Lille), CHRU de Lille and U995 Inserm, and Université Nord de France, Lille, France.
¹⁵ Centre de l'Asthme et des Allergies, Hôpital d'Enfants Armand-Trousseau, Paris, France INSERM, UMR_S 1136, Sorbonne Universités, UPMC Université Paris 06, Paris, France Institut Pierre Louis d'Epidémiologie et de Santé Publique, Equipe EPAR, Paris, France.

PMID: 26022964
DOI: 10.1183/09031936.00008115

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Anti-Asthmatic Agents / adverse effects
Anti-Asthmatic Agents / therapeutic use*
Antibodies, Monoclonal, Humanized / adverse effects
Antibodies, Monoclonal, Humanized / therapeutic use*
Asthma / drug therapy*
Asthma / immunology*
Asthma / physiopathology
Child
Cohort Studies
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Follow-Up Studies
Humans
Injections, Subcutaneous
Long-Term Care
Male
Omalizumab / therapeutic use*
Recurrence
Retrospective Studies
Severity of Illness Index
Treatment Outcome

Substances

Anti-Asthmatic Agents
Antibodies, Monoclonal, Humanized
Omalizumab